PMID- 33623533
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210225
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - Effects of Novel Anti-VEGF Agents with Intravitreal Conbercept in Diabetic 
      Retinopathy: A Systematic Review and Meta-Analysis.
PG  - 9357108
LID - 10.1155/2021/9357108 [doi]
LID - 9357108
AB  - To evaluate the efficacy and safety of intravitreal conbercept (IVC) for diabetic 
      retinopathy (DR) compared with intravitreal triamcinolone acetonide (IVTA). 
      PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, VIP 
      database, and Wanfang database were searched from their earliest records to 
      January 2020. We included randomized controlled trials (RCTs) evaluating the 
      efficacy and safety of conbercept in DR patients compared with ITVA. Outcomes 
      included the mean changes from the baseline in best corrected visual acuity 
      (BCVA) score, central macular thickness (CMT), quality of life (QoL) over time, 
      and the incidence of adverse events (AEs). A total of 19 RCTs involving 1,811 
      eyes were included in this meta-analysis. IVC might improve BCVA (WMD = 0.10, 95% 
      CI (0.07, 0.12), P < 0.001) and reduce CMT (WMD = -102.5, 95% CI (-148.48, 
      -56.53), P < 0.001) compared to IVTA. The incidence of AEs in patients receiving 
      IVC was significantly lower than those receiving IVTA (RR = 0.29, 95% CI (0.21, 
      0.40), P < 0.001). Patients with IVC treatments acquired better self-care, 
      mobility, social, and mental scores compared with IVTA (P < 0.001). Current 
      evidence shows that IVC has better effects and safety than IVTA in treating DR, 
      and it can significantly enhance the QoL of patients with DR.
CI  - Copyright (c) 2021 Hui Wang et al.
FAU - Wang, Hui
AU  - Wang H
AUID- ORCID: 0000-0003-4905-466X
AD  - Department of Ophthalmology, The 4th People's Hospital of Shenyang, Shenyang, 
      Liaoning 110031, China.
FAU - Zhou, Jing
AU  - Zhou J
AD  - Department of Ophthalmology, The 4th People's Hospital of Shenyang, Shenyang, 
      Liaoning 110031, China.
FAU - Sun, Caoyu
AU  - Sun C
AD  - Department of Ophthalmology, The 4th People's Hospital of Shenyang, Shenyang, 
      Liaoning 110031, China.
FAU - Dong, Xu
AU  - Dong X
AD  - Department of Ophthalmology, The 4th People's Hospital of Shenyang, Shenyang, 
      Liaoning 110031, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210203
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7875627
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/02/25 06:00
MHDA- 2021/02/25 06:01
PMCR- 2021/02/03
CRDT- 2021/02/24 05:43
PHST- 2020/07/26 00:00 [received]
PHST- 2021/01/25 00:00 [accepted]
PHST- 2021/02/24 05:43 [entrez]
PHST- 2021/02/25 06:00 [pubmed]
PHST- 2021/02/25 06:01 [medline]
PHST- 2021/02/03 00:00 [pmc-release]
AID - 10.1155/2021/9357108 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Feb 3;2021:9357108. doi: 
      10.1155/2021/9357108. eCollection 2021.